This study will evaluate the long-term safety and tolerability of NBI-1065845 as an adjunctive treatment in participants with MDD.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Timeframe: Baseline through Week 52
Neurocrine Medical Information Call Center